E
Evaristo Varo
Researcher at University of Santiago de Compostela
Publications - 51
Citations - 1491
Evaristo Varo is an academic researcher from University of Santiago de Compostela. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 15, co-authored 51 publications receiving 1309 citations.
Papers
More filters
Journal ArticleDOI
Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma
Ricardo Robles,Joan Figueras,Víctor Sánchez Turrión,Carlos Margarit,Angel Moya,Evaristo Varo,Javier Calleja,Andrés Valdivieso,Juan Carlos G. Valdecasas,Pedro García López,Manuel Gómez,Emilio Vicente,Carmelo Loinaz,Julio Santoyo,Manuel Fleitas,Angel Bernardos,Laura Lladó,Pablo Ramírez,Francisco Sánchez Bueno,Eduardo Jaurrieta,Pascual Parrilla +20 more
TL;DR: OLT for nondisseminated irresectable cholangiocarcinoma has higher survival rates at 3 and 5 years than palliative treatments, especially with tumors in their initial stages, which means that more information is needed to help better select cholangeous liver transplantation patients for transplantation.
Journal ArticleDOI
Analysis of the complications of the piggy-back technique in 1,112 liver transplants.
Pascual Parrilla,Francisco Sánchez-Bueno,Juan Figueras,Eduardo Jaurrieta,José Mir,Carlos Margarit,J Lázaro,L Herrera,M Gomez-Fleitas,Evaristo Varo,Emilio Vicente,Ricardo Robles,Pablo Ramírez +12 more
TL;DR: The vena cava preservation technique can be used routinely in orthotopic liver transplantation because it is safe and efficient and involves few surgical complications especially if for venous reconstruction the authors use the patch obtained by joining the three suprahepatic veins.
Journal ArticleDOI
Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study
G. Sapisochin,C. Rodríguez de Lope,Mikel Gastaca,J. Ortiz de Urbina,Rafael López-Andújar,F. Palacios,Emilio Ramos,Joan Fabregat,J.F. Castroagudin,Evaristo Varo,José Antonio Pons,Pascual Parrilla,M.L. González-Diéguez,Macarena Rodriguez,Alejandra Otero,Mercedes Vázquez,Gabriel Zozaya,J.I. Herrero,G. Sanchez Antolin,B. Perez,Ruben Ciria,S. Rufian,Y. Fundora,J. A. Ferron,A. Guiberteau,Gerardo Blanco,M. A. Varona,M. A. Barrera,M. A. Suarez,Julio Santoyo,Jordi Bruix,Ramón Charco +31 more
TL;DR: Patients with HCC-CC have similar survival to patients undergoing a transplant for HCC and preoperative diagnosis of HCC should not prompt the exclusion of these patients from transplant option.
Journal ArticleDOI
"Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?
G. Sapisochin,C. Rodríguez de Lope,Mikel Gastaca,J. Ortiz de Urbina,M. A. Suarez,Julio Santoyo,J.F. Castroagudin,Evaristo Varo,Rafael López-Andújar,F. Palacios,G. Sanchez Antolin,B. Perez,A. Guiberteau,Gerardo Blanco,M.L. González-Diéguez,Manuel Rodríguez,María Aranzazu Varona,Manuel Barrera,Y. Fundora,J. A. Ferron,Emilio Ramos,Joan Fabregat,Ruben Ciria,S. Rufian,Alejandra Otero,Mercedes Vázquez,José Antonio Pons,Pascual Parrilla,Gabriel Zozaya,J.I. Herrero,Ramón Charco,Jordi Bruix +31 more
TL;DR: Cirrhotic patients with iCCA ≤2 cm achieved excellent 5‐year survival, and validation of these findings by other groups may change the current exclusion of such patients from transplant programs.
Journal ArticleDOI
Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease
Santiago Tomé,Carmen Martínez-Rey,Arturo Gonzalez-Quintela,Francisco Gude,Antonio Brage,Esteban Otero,Ihab Abdulkader,Jerónimo Forteza,Manuel Bustamante,Evaristo Varo +9 more
TL;DR: Survival after liver transplantation in patients with alcoholic cirrhosis plus alcoholic hepatitis detected in the explanted liver is similar to that of patients transplanted for other reasons, suggesting that the presence of severe alcoholic hepatitis does not worsen the outcome of liver transplation for end-stage alcoholic liver disease.